Press Releases Items Per Page 102550 Year None201920182017201620152014 09-11-2019 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics 09-09-2019 Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder 09-04-2019 Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference 08-14-2019 Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update 08-12-2019 Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis 08-08-2019 Daré Announces Presentation of Positive Clinical Findings for Vaginal Administration of Novel Formulation of Clindamycin Phosphate for the Treatment of Bacterial Vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology 08-06-2019 Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast 07-22-2019 Daré Announces Presentation of Two Posters at the 2019 Controlled Release Society Annual Meeting & Exposition 07-17-2019 Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model 07-15-2019 Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 30
09-11-2019 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics
09-09-2019 Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
09-04-2019 Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference
08-12-2019 Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis
08-08-2019 Daré Announces Presentation of Positive Clinical Findings for Vaginal Administration of Novel Formulation of Clindamycin Phosphate for the Treatment of Bacterial Vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology
08-06-2019 Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast
07-22-2019 Daré Announces Presentation of Two Posters at the 2019 Controlled Release Society Annual Meeting & Exposition
07-17-2019 Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model
07-15-2019 Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors
